Percutaneous Coronary Interventions in Patients With ST-Elevation Myocardial Infarction: 10-Years Follow-up

Aim      To study long-term results and to identify predictors of death in patients with ST-segment elevation acute myocardial infarction (STEMI) who underwent endovascular revascularization.

Materials and methods This study included 283 patients registered in the hospital registry of percutaneous coronary interventions (PCI) for STEMI from 2006 through 2009. Analysis of 10-year results included all-cause and cardiovascular death rate, incidence of recurrent myocardial infarction (MI), repeated revascularization, stroke, stent restenosis and thrombosis. Also, a composite endpoint МАССЕ (Major Adverse Cardiovascular and Cerebrovascular Events) was evaluated, which included death, recurrent MI, repeated PCI, stent restenosis and thrombosis, coronary bypass, and stroke.

Results Information about the health condition was provided by 204 (72.1 %) patients. Mean follow-up period was 120.1±9.5 months. All-cause mortality was 25.5 % with cardiovascular death determined in 19.1 % of cases. Recurrent MI developed in 21.6 % of patients; in 1.5 % of cases, recurrent MI resulted from thrombosis of previously implanted stents. Repeated PCI was performed for 31.9 % of patients; in 13.7 % of cases, the PCI was performed for stent restenosis. Coronary bypass was performed for 5.4 % of patients. Incidence of stroke was 10.3 %. Major cardiovascular and cerebrovascular complications (МАССЕ) during the follow-up period were determined in 60.3 % patients. According to the Cox proportional hazards regression model, age ≥65 years (odds ratio (OR), 3.75 at 95 % confidence interval (CI) from 1.75 to 8.03; р=0.001) and incomplete coronary revascularization (OR, 3.09 at 95 % CI from 1.52 to 6.30; р=0.002) were independent predictors of death based on data of the 10-year observation.

Conclusion      Therefore, at 10 years following endovascular revascularization, STEMI patients showed a moderate death rate with a high incidence of major cardiovascular and cerebrovascular complications. The leading causes for fatal outcomes were recurrent cardiovascular complications. The major predictors of death for the coming 10-year period included age ≥65 years and incomplete myocardial revascularization.

1. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal. 2019;40(2):87–165. DOI: 10.1093/eurheartj/ehy394

2. Kuznetsov V.A., Yaroslavskaya E.I., Pushkarev G.S., Zyryanov I.P., Bessonov I.S., Gorbatenko E.A. et al. Interrelation of transcutaneous coronary interventions for acute forms of coronary heart disease and mortality parameters in tyumen region inhabitants. Russian Journal of Cardiology. 2014;19(6):42–6. DOI: 10.15829/1560-4071-2014-6-42-46

3. Аlekyan B.G., Grigor’yan А.M., Staferov А.V. X-ray endovascular diagnostics and treatment of heart and vascular diseases in the Russian Federation 2016 year. -M.: LA Graphics;2017. - 220 p. ISBN 978-5-4465-1503-5

4. Garganeeva A.A., Kuzheleva E.A., Aleksandrenko V.A. Populational study of long term outcomes of acute myocardial infarction in Tomsk. Russian Journal of Cardiology. 2017;22(11):27–30. DOI: 10.15829/1560-4071-2017-11-27-30

5. Konttila KK, Koivula K, Eskola MJ, Martiskainen M, Huhtala H, Virtanen VK et al. Poor long-term outcome in acute coronary syndrome in a real-life setting: Ten-year outcome of the TACOS study. Cardiology Journal. 2019; [Epub ahead of print]. DOI: 10.5603/CJ.a2019.0037

6. Ellis CJ, Gamble GD, Williams MJA, Matsis P, Elliott JM, Devlin G et al. All- Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit. Heart, Lung and Circulation. 2019;28(2):245–56. DOI: 10.1016/j.hlc.2017.10.015

7. Barchielli A, Santoro GM, Balzi D, Carrabba N, Di Bari M, Gensini GF et al. Long-term prognosis after primary PCI in unselected patients with ST-elevation myocardial infarction: Journal of Cardiovascular Medicine. 2012;13(12):819–27. DOI: 10.2459/JCM.0b013e328356a29c

8. Giurgea G-A, Heuberger A, Babayev J, Winkler S, Schlager O, Lang IM et al. 9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Liberté stents. PLOS ONE. 2018;13(8):e0201416. DOI: 10.1371/journal.pone.0201416

9. Plakht Y, Shiyovich A, Gilutz H. Predictors of long-term (10-year) mortality postmyocardial infarction: Age-related differences. Soroka Acute Myocardial Infarction (SAMI) Project. Journal of Cardiology. 2015;65(3):216–23. DOI: 10.1016/j.jjcc.2014.06.001

10. 10. Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine. 2019;381(15):1411–21. DOI: 10.1056/NEJMoa1907775

11. Bainey KR, Mehta SR, Lai T, Welsh RC. Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A systematic review and meta-analysis. American Heart Journal. 2014;167(1):1-14.e2. DOI: 10.1016/j.ahj.2013.09.018

12. Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N et al. Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease. Journal of the American College of Cardiology. 2015;65(10):963–72. DOI: 10.1016/j.jacc.2014.12.038

13. Engstrøm T, Kelbæk H, Helqvist S, Høfsten DE, Kløvgaard L, Holmvang L et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. The Lancet. 2015;386(9994):665–71. DOI: 10.1016/S0140-6736(15)60648-1

14. Tarasov R.S., Ganyukov V.I., Protopopov A.V., Barbarash O.L., Barbarash L.S. Results of a Randomized Study: Multivessel Stenting and Staged Revascularization in Patients With ST-Elevation Myocardial Infarction Using Second Generation Drug Covered Stents. Kardiologiia. 2017;57(3):25–30. DOI: 10.18565/cardio.2017.3.25-30

15. Wood DA, Cairns JA, Wang J, Mehran R, Storey RF, Nguyen H et al. Timing of Staged Nonculprit Artery Revascularization in Patients With ST- Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 2019;74(22):2713–23. DOI: 10.1016/j.jacc.2019.09.051

16. Bessonov I.S., Kuznetsov V.A., Zyrianov I.P., Sapozhnikov S.S., Potolinskaya Yu.V., Zyrianova T.I. Comparison of Direct Stenting Versus Stending After Pre-Dilation in ST-Elevation Myocardial Infarction. Kardiologiia. 2017;57(11):5–10. DOI: 10.18087/cardio.2017.11.10048

17. Bessonov I.S., Kuznetsov V.A., Potolinskaya Yu.V., Zyrianov I.P., Sapozhnikov S.S. Impact of hyperglycemia on the results of percutaneous coronary interventions in patients with acute ST-segment elevation myocardial infarction. Therapeutic Archive. 2017;89(9):25–9. DOI: 10.17116/terarkh201789925-29

18. Barbarash O.L., Sedykh D.Yu., Gorbunova E.V. Key factors determining the risk of recurrent myocardial infarction. Russian Heart Journal. 2017;16(1):26–31. DOI: 10.18087/rhj.2017.1.2280